1. Introduction {#sec1-marinedrugs-18-00002}
===============

The potential of microalgae as source of novel drugs has recently generated a great interest for the scientific community. Microalgae are a source of several bioactive compounds such as vitamins, lipids, carbohydrates, and pigments. Several studies showed that microalgal raw extracts, fractions, and pure compounds had biological activities \[[@B1-marinedrugs-18-00002]\], such as anticancer \[[@B2-marinedrugs-18-00002]\], anti-microbial \[[@B3-marinedrugs-18-00002]\], anti-epilepsy \[[@B4-marinedrugs-18-00002]\], anti-inflammatory \[[@B5-marinedrugs-18-00002],[@B6-marinedrugs-18-00002]\], and immunomodulatory activities \[[@B7-marinedrugs-18-00002]\].

The use of marine macroorganisms for drug discovery and massive production is very often limited by the sourcing and by the difficulties in culturing and scaling up \[[@B8-marinedrugs-18-00002]\]. On the contrary, microalgae can be easily cultivated in small or large volumes (e.g., by using photobioreactors) in order to obtain huge amount of the desired products \[[@B3-marinedrugs-18-00002],[@B9-marinedrugs-18-00002]\] and their harvesting does not depend on seasons and climate. In addition, changes in cultivation conditions (i.e., light, temperature, bubbling, nutrient concentrations, salinity) may direct the synthesis of compounds of interest and increase their production \[[@B10-marinedrugs-18-00002],[@B11-marinedrugs-18-00002],[@B12-marinedrugs-18-00002],[@B13-marinedrugs-18-00002],[@B14-marinedrugs-18-00002],[@B15-marinedrugs-18-00002]\].

Microalgae are adapted to live in both marine and freshwater environments, as well as in extreme conditions (e.g., hot, cold, high/low salinity, high/low light intensities, etc.,). This capability resulted in a huge diversity of species which can produce very different interesting natural products \[[@B16-marinedrugs-18-00002]\] with industrial and pharmaceutical interest \[[@B17-marinedrugs-18-00002]\]. Recent technologies have allowed to sequence genomes, metagenomes, transcriptomes, metatranscriptomes, proteomes, and metabolomes of several species or pool of species, in silico identifying gene clusters involved in the synthesis of potentially bioactive compounds and helping in the discovery of new drugs from microalgae \[[@B18-marinedrugs-18-00002],[@B19-marinedrugs-18-00002]\].

Recently, various compounds from microalgae have been found to stimulate the immune system in human and murine models (e.g., modifying macrophage activations and the release of pro- and anti-inflammatory mediators \[[@B20-marinedrugs-18-00002],[@B21-marinedrugs-18-00002],[@B22-marinedrugs-18-00002]\]) and they are promising drugs with potential applications to treat human pathologies \[[@B2-marinedrugs-18-00002],[@B7-marinedrugs-18-00002],[@B23-marinedrugs-18-00002]\].

The immune system has developed a broad array of defensive mechanisms to protect the host from a high variety of pathogenic organisms and toxic substances. These mechanisms may be classified into two categories: (1) innate immune response; (2) adaptive immune response. Innate immune response acts rapidly after an invading pathogen. It involves a large number of cells and molecules, thus constitutes the first host response. Innate immune cells include basophils, dendritic cells, eosinophils, monocytes and macrophages, neutrophils and natural killer (NK) cells \[[@B24-marinedrugs-18-00002]\]. On the contrary, adaptive immune response involves a few number of cells and it is based on the antigen-specific receptor expressed on adaptive immune cells, T and B lymphocytes \[[@B25-marinedrugs-18-00002]\]. Immune system cells regulate their activities through a plethora of different mediators. Cellular mediators of these processes are cytokines, that include interleukins, tumor necrosis factor α (TNF-α), and interferon γ (INF-γ) produced predominantly by macrophages and lymphocytes \[[@B26-marinedrugs-18-00002]\]. In addition, another cell-signaling messenger in a wide range of physiological and pathophysiological processes \[[@B27-marinedrugs-18-00002]\] is nitric oxide (NO). Moreover, uncontrolled immune responses to pathogens or toxic substances can cause inflammatory tissue damages and autoimmune diseases. To prevent these effects, the magnitude of the immune response is regulated by a balance between co-stimulatory and inhibitory signals \[[@B28-marinedrugs-18-00002]\]. T cells are primary mediators of immune effector functions and they express multiple co-inhibitory receptors including lymphocyte-activation gene 3 (LAG-3), programmed cell death protein 1 (PD-1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) \[[@B28-marinedrugs-18-00002]\].

Immunomodulation includes all the processes to modify/regulate the immune response for therapeutic aims. Thus immunomodulation includes the activation of immune system to reduce inflammatory processes (e.g., immune system response to injury and infection) and fight diseases such as microbial infections and cancer (e.g., vaccination to fight infection by pathogenic agents or more recently immunotherapy to fight cancer). The last two decades have seen a crescendo of immunotherapeutic agents against tumors approved by Food and Drug Administration (FDA) \[[@B29-marinedrugs-18-00002]\].

The research of novel and nontoxic compounds from natural sources for cancer treatments is necessary because of toxicity and sometimes low specificity of chemotherapy and radiotherapy, as well as adverse reactions in patients. Both innate and adaptive immune system may be engaged against cancer \[[@B30-marinedrugs-18-00002],[@B31-marinedrugs-18-00002]\] and there are different ways in which immune system can be used against cancer disease: Vaccination: traditionally, vaccination stimulated immune response using inactivated biological agents. Recent vaccines consist of highly purified synthetic macromolecules combined with adjuvant agents. Adjuvant agents potentiate the immune response by activating the antigen-presenting cells (APCs) \[[@B32-marinedrugs-18-00002],[@B33-marinedrugs-18-00002]\].Immune checkpoint blockage: it is an innovative treatment that uses immune checkpoint inhibitors. Specific protein expressed by immune system cells or by cancer cells, such as PD-1 and PD-L1 \[[@B34-marinedrugs-18-00002],[@B35-marinedrugs-18-00002]\], CTL-4 \[[@B36-marinedrugs-18-00002]\], STAT-3 \[[@B37-marinedrugs-18-00002]\] can be inhibited to induce T-cell to kill cancer cell \[[@B38-marinedrugs-18-00002]\].Monoclonal antibodies: monoclonal antibodies can be targeted against tumor specific antigens and they can trigger cell death by different mechanisms of action \[[@B39-marinedrugs-18-00002],[@B40-marinedrugs-18-00002]\].CAR-T cells: Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy consist in engineered T-cell redirected against a specific target. CAR-T therapy has shown a high rates of success (good outcome) against acute and chronic leukemia \[[@B41-marinedrugs-18-00002]\].

This review is focused on microalgae with immunomodulatory activity, active microalgal raw extracts, fractions, the most promising immunomodulatory compounds and the mechanisms of action, giving an overview of their pharmaceutical potential.

2. Microalgae with Anti-Inflammatory Activity {#sec2-marinedrugs-18-00002}
=============================================

Anti-inflammatory properties were previously found for various marine diatoms, such as Porosira glacialis, *Attheya longicornis* \[[@B42-marinedrugs-18-00002]\], *Cylindrotheca closterium*, *Odontella mobiliensis*, *Pseudonitzschia pseudodelicatissima* \[[@B43-marinedrugs-18-00002]\] and *Phaeodactylum tricornutum* \[[@B44-marinedrugs-18-00002]\], for the dinoflagellate *Amphidinium carterae* \[[@B44-marinedrugs-18-00002]\] and the green algae *Dunaliella bardawil* and *Dunaliella tertiolecta* \[[@B45-marinedrugs-18-00002]\]. Lauritano et al. 2016 \[[@B43-marinedrugs-18-00002]\] and Ingebrigstein et al. \[[@B42-marinedrugs-18-00002]\] evaluated the release of one of the main effectors of inflammation, the tumor necrosis factor α (TNFα) \[[@B46-marinedrugs-18-00002]\] in lipopolysaccharide (LPS)-stimulated monocytic leukemia cells (THP-1). Samarakoon et al. \[[@B44-marinedrugs-18-00002]\] tested the inhibition of nitric oxide (NO) production (%) level, one of the inflammatory mediators, as positive evidence of anti-inflammatory activity on LPS-induced RAW macrophages.

In a double-blind placebo-controlled randomized clinical trials, seventy patients, affected by non-alcoholic fatty liver disease (NAFLD) were recruited to test the effects of *Chlorella vulgaris*. 300 mg tablet commercially available as ALGOMED® of *C. vulgaris* supplements contained 98% *C. vulgaris* powder, 1% separating agent, 1% plant-based magnesium stearate were administered. For eight weeks, patients received four tablets/day of *C. vulgaris*. The patients treated with *C. vulgaris* tablets had significantly lower serum levels of the pro-inflammatory cytokine TNF-α \[[@B47-marinedrugs-18-00002]\].

Finally, Lavy et al. 2003 \[[@B45-marinedrugs-18-00002]\], showed protective effects of spray-dried *D. bardawil* powder against acetic acid-induced small bowel inflammation in rats, while Caroprese et al. \[[@B48-marinedrugs-18-00002]\] showed that a mixture of phytosterols from *D. tertiolecta* reduced the cytokine production in a sheep model of inflammation. Except for the last case, no much information is available on the compounds responsible for the anti-inflammatory activity observed in the mentioned studies.

In addition, there are some studies reporting the anti-inflammatory activity of pure compounds isolated from both marine and freshwater microalgae: the carotenoids lutein and astaxanthin, the fatty acids EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), and sulphated polysaccharides (sPS) \[[@B5-marinedrugs-18-00002]\].

Ingebrigtsen et al. and Lauritano et al. also used an OSMAC (one strain-many compounds) approach changing culturing condition parameters, such as nutrients \[[@B43-marinedrugs-18-00002]\], light, and temperature \[[@B42-marinedrugs-18-00002]\], in order to trigger anti-inflammatory activity. They observed that the studied species were active only in specific conditions highlighting the importance of selecting the proper parameters to increase bioactivity of microalgal extracts. Similarly, Montero-Lobato et al. (2018) \[[@B5-marinedrugs-18-00002]\] reported the chemical triggers (e.g., low oxygen, NaCl and nutrient starvation) to increase the production of anti-inflammatory molecules (i.e., carotenoids, fatty acids, and sulphated polysaccharides) from some microalgal species (e.g., *Chlorella zofingiensis, Coccomyxa onubensis*, *Cromochloris zofingiensis*, *Dunaliella salina*, *D. tertiolecta*, *Haematococcus pluvialis*, *Nannochloropsis oceanica*, *Pavlova lutheri*, *P. tricornutum*, and *Spirulina platensis*).

3. Microalgae with Immunomodulatory Activity {#sec3-marinedrugs-18-00002}
============================================

To date several microalgae have been found to have immunomodulatory activity in human or in other organisms (i.e., sheep and mouse); however, the compounds responsible for this activity are often still unknown. As reported in [Table 1](#marinedrugs-18-00002-t001){ref-type="table"}, dried algae and raw extracts were active against several immune cells. Cutignano et al. \[[@B49-marinedrugs-18-00002]\] tested raw methanolic extracts and fractions derived from them (named A-E) of various microalgal species (i.e., *Alexandrium andersoni FE108*, *Alexandrium tamarense FE107*, *Chaetoceros calcitrans FE20*, *C. socialis FE17*, *Ditylum brightwellii*, *D. salina FE209*, *Skeletonema costatum RCC1716*, *S. dohrnii FE82*, *S. marinoi FE65*, *S. pseudo-costatum FE25*, *Skeletonema* sp. KS5 and *Thalassiosira weissflogii 1336*) on human peripheral blood mononuclear cells (PBMCs). Immunostimulant activity in this study was considered as induction of IL-6 in PBMCs cells. They found that raw methanolic extracts were active for *S. costatum* and *S. dohrni.* Fractionation allowed for these two species to identify the active fractions. Triglycerides rich fraction (named fraction E) was active for *S. costatum*, while nucleoside rich fraction (named fraction B) was active for *S. dohrnii.* For other species whose raw methanolic extracts were not active, fractionation also helped to identify active fractions. This is probably due to the fact that fractions contained less salt (mainly NaCl) than primary extracts. In particular, glycololipidic and phospholipidic fraction (named fraction C) was active for *A. tamarense*, nucleosides rich fraction (named fraction B) was active for *D. salina,* amminoacids and saccarides rich fraction (named fraction A) was active for *C. calcitrans*, while glycolipidic and phospholipidic fraction (fraction C) and the fraction rich in free fatty acids and sterols (named fraction D) were active for *T. weissflogii.*

Other extracts derived from microalgae have been tested to evaluate their immunostimulatory activity. *Chlorella stigmatophora* polysaccharide extracts (aqueous extracts) have been tested in in vitro and in vivo mouse models. In particular, the BALB/c mice were injected with 5 mg of polysaccharide extracts per kg of body weight in order to test the phagocytic activity by using macrophages from peritoneal cavity both for in vitro and in vivo assays. The C57BI mice were injected with polysaccharide extracts at 5 mg or 10 mg per kg of body weight, two days before or two days after the injection of sheep red blood cells (SRBC). This experiment was performed in order to test the activation on SRBC \[[@B50-marinedrugs-18-00002]\]. Both experiments showed that *C. stigmatophora* polysaccharide extracts were able to activate phagocytic activity of macrophages from the peritoneal cavity.

*Euglena gracilis* β-glucans (called paramylon) at 150 µg/ml activated NK cells and increased the levels of the two pro-inflammatory mediators TNF-α and IL-6 \[[@B51-marinedrugs-18-00002],[@B52-marinedrugs-18-00002]\]. *Gyrodinium impudicum* KG03 sulfated exopolysaccharides (at 0.1--10 µg/ml) induced cellular response in peritoneal macrophages in in vitro murine models \[[@B53-marinedrugs-18-00002]\]. In addition, sulphated polysaccharides extracted from *Tribonema* sp have been found to enhance macrophage cell viability and improve the expression of cytokines. Authors found that cell viability was only improved in the presence of 25 µg/mL of sulfated polysaccharides, while the cytokine expression increased with sulfated polysaccharide treatment at 12.5--200 µg/mL \[[@B2-marinedrugs-18-00002]\]. Park et al. \[[@B54-marinedrugs-18-00002]\] tested the immunostimulatory activity of *Thraustochytriidae* sp. on human lymphocyte B-cells. They found that the polysaccharides from this alga tested at 10^−3^ to 10^−9^ w/v were able to stimulate cell proliferation but not cytokine production.

Double-blind placebo-controlled randomized clinical trials have also been performed to test the in vivo immunostimulatory activity of *C. vulgaris*. Sixty people were recruited and randomly assigned to placebo group or *Chlorella* group. Tested pills contained dried *C. vulgaris* as active ingredient (Daesang Corp., Seoul, Korea). The diet was supplemented with 5 g/day of *C. vulgaris*. All participants were encouraged to maintain their usual lifestyle and dietary habits. *C. vulgaris*-supplemented diet improved NK activity from PBMCs isolated from the treated patients and increased the serum level of INF-γ, IL-1β and IL-12 \[[@B55-marinedrugs-18-00002]\].

Microalgae food supplementation has also been associated to immunostimulatory activity. Indeed, diet supplementation of commercially available spray-dried preparations of *D. salina* (369 or 922.5 mg of algal extract per kg of body weight) in mice improved NK and macrophage activation, as well as survival rate of leukemic mice \[[@B56-marinedrugs-18-00002]\]. Orally administration of *Tetraselmis chuii* (50 or 100 g of lyophilized alga per kg of dried food) in gilthead seabream (*Sparus aurata* L) induced an increase in expression levels of several genes associated to immune system, such as T-cell receptor beta (TCR-β), major histocompatibility complex genes and IgM \[[@B57-marinedrugs-18-00002]\].

Most of these compounds act as vaccine adjuvants improving the immune response by activating APCs \[[@B7-marinedrugs-18-00002],[@B49-marinedrugs-18-00002],[@B58-marinedrugs-18-00002]\]. In [Table 1](#marinedrugs-18-00002-t001){ref-type="table"}, we have summarized the algae which have shown immunostimulatory activity. Pure compounds from microalgae with immunomodulatory activity will be discussed in the next paragraph.

4. Immunomodulatory Compounds from Microalgae {#sec4-marinedrugs-18-00002}
=============================================

4.1. Sulfate Polysaccharides {#sec4dot1-marinedrugs-18-00002}
----------------------------

Microalgae are known to be excellent producers of polysaccharides (PS), including exocellular polysaccharides (EPS) and sulphated polysaccharides (sPS). PS have been shown to be good antiviral agents, health foods, antioxidants, anti-inflammatory, and immunomodulatory compounds, and they can also be used as lubricants for bone joints and drag-reducing substances for ships \[[@B62-marinedrugs-18-00002]\]. sPS from marine sources exhibited, in particular, immunomodulatory activities \[[@B2-marinedrugs-18-00002],[@B63-marinedrugs-18-00002],[@B64-marinedrugs-18-00002],[@B65-marinedrugs-18-00002],[@B66-marinedrugs-18-00002],[@B67-marinedrugs-18-00002],[@B68-marinedrugs-18-00002],[@B69-marinedrugs-18-00002]\], and are promising candidates for drug development. sSP have been found in several macroalgae and microalgae, in both marine and freshwater environments, such as in the green alga *Monostroma nitidum* \[[@B70-marinedrugs-18-00002]\], the red algae *Gelidum corneum* \[[@B67-marinedrugs-18-00002]\] and *Gracilaria caudata* \[[@B71-marinedrugs-18-00002]\], the diatom *P. tricornutum* \[[@B23-marinedrugs-18-00002]\], the dinoflagellate *G. impudicum,* the freshwater xanthophycea *Tribonema* sp. \[[@B2-marinedrugs-18-00002]\] and others \[[@B58-marinedrugs-18-00002]\].

Regarding the mechanisms of action evaluated for sPS extracted from microalgae few studies have reported details. In particular, Chen et al. \[[@B2-marinedrugs-18-00002]\] and Bahramzadah et al. \[[@B68-marinedrugs-18-00002]\] tested the immunostimulatory effects of sPS extracted from *Tribonema* sp. (12.5--200 μg/mL or 10--50 μg/mL respectively) on RAW 264.7 murine macrophage cells. The results of these two independent studies showed a macrophage cell stimulation characterized by the up-regulation of interleukin-6 (IL-6), interleukin-10 (IL10), and tumor necrosis factor alpha (TNF-α) levels after 24 h of sPS treatment. Bae et al. \[[@B53-marinedrugs-18-00002]\] tested the activity of the sPS from the dinoflagellate *G. impudicum* on murine peritoneal macrophages. In particular, murine macrophages were co-incubated with B16 mouse melanoma cells in the absence and in the presence of sPS. sPS increased cytotoxicity in macrophages and there was an increase in nitric oxide production but not in IL-1, IL-6, and TNF-α expression.

4.2. Sulfolipids {#sec4dot2-marinedrugs-18-00002}
----------------

Sulfolipids are constituents of the thylakoid in plant and algal chloroplasts \[[@B72-marinedrugs-18-00002]\] and they constitute the anionic fraction of the mono- and digalactosyl-diacylglycerols \[[@B73-marinedrugs-18-00002]\]. Sulfoquinovose ([Figure 1](#marinedrugs-18-00002-f001){ref-type="fig"}a), the building block of sulfolipids ([Figure 1](#marinedrugs-18-00002-f001){ref-type="fig"}b), is also the major component of the biological sulphur cycle \[[@B74-marinedrugs-18-00002]\] and it is produced by photosynthetic organisms at a rate of 1010 tons per year \[[@B75-marinedrugs-18-00002]\].

Sulfolipids have been found to have several potential activities to treat and prevent human pathologies. For instance, it was demonstrated that they are potent glutaminyl cyclase inhibitors, with possible applications against Alzheimer's disease \[[@B76-marinedrugs-18-00002]\]. In addition, sulfolipids have been shown to be able to activate the immune system, with application as vaccine adjuvants \[[@B7-marinedrugs-18-00002]\]. In particular, Manzo et al. \[[@B7-marinedrugs-18-00002]\] used microalgae-derived sulfolipids as lead compounds to generate a synthetic sulfoglycolipid (called β-SQDG18) as vaccine adjuvant to trigger a more effective dendritic cell (DC) activation and improve immune response against cancer cell (i.e., B16 mouse melanoma cells). β-SQDG18, tested at 0.01 to 10 μg/mL on DCs, increased the percentage of CD83-positive DCs, stimulated the production of the pro-inflammatory cytokines IL-12 and INF-γ and increased the expression levels of IL-1α, IL-1β, IL-18, and IL-27 after 24 h exposure. β-SQDG18 was also tested at 25 mg via subcutaneous injection in a model of cancer vaccine against B16 mouse melanoma cells, the synthetic sulfolipids were able to reduce tumor growth and induce expansion of both lymphocytes and APCs memory in the treated mice, thus resulting a good adjuvant in cancer vaccination. This synthetic sulfolipids was patented as Sulfavant (EP3007725A1, WO2014199297A1). Moreover, the inventors improved the sulfavant synthesis and modified it producing two epimers named Salfavant-S and Sulfavant-R, that induced a more effective immune response (increase in IL-12 and INF-γ levels) \[[@B77-marinedrugs-18-00002]\].

4.3. Polyunsaturated Fatty Acids (PUFAs) {#sec4dot3-marinedrugs-18-00002}
----------------------------------------

PUFAs are fatty acids that contain two or more double bonds in their carbon chain. There are two well-known classes of PUFA, namely omega-6 (ω-6) and omega-3 (ω-3) series. The position of the first unsaturation on carbon backbone from the methyl, omega-C, generated the name of the two different classes. Microalgae are important source of polyunsaturated fatty acids and they are able to synthesize both omega 6 and omega 3 fatty acids and several species of microalgae have been characterized for their PUFA production ([Table 2](#marinedrugs-18-00002-t002){ref-type="table"}). Considering the continuous reduction of available fishery and seafood resources and the increasing market request of vegan products, microalgae have been considered as valuable alternatives, as well as sustainable and eco-friendly PUFA producers \[[@B78-marinedrugs-18-00002]\]. The omega 6 fatty acids class include γ-linoleic acid (GLA) and arachidonic acid (ARA), the omega 3 fatty acid class include eicosapentaeonic acid (EPA), known as the most abundant PUFA in phytoplankton \[[@B79-marinedrugs-18-00002]\], and docosahexaeonic acid (DHA) ([Figure 2](#marinedrugs-18-00002-f002){ref-type="fig"}) \[[@B80-marinedrugs-18-00002]\]. Diatoms are the principal omega 3 fatty acid producing algae, especially EPA and DHA \[[@B81-marinedrugs-18-00002]\]. In [Table 2](#marinedrugs-18-00002-t002){ref-type="table"}, we report the microalgae for which the most abundant PUFAs produced were studied.

Several biological functions have been associated to DHA and EPA, such as a wide range of beneficial cardiovascular effects \[[@B82-marinedrugs-18-00002]\], antimicrobial activities \[[@B83-marinedrugs-18-00002]\], anti-inflammatory modulation \[[@B84-marinedrugs-18-00002]\], antioxidant properties \[[@B85-marinedrugs-18-00002]\], beneficial effects on respiratory diseases \[[@B86-marinedrugs-18-00002],[@B87-marinedrugs-18-00002]\], antitumoral activity \[[@B88-marinedrugs-18-00002]\], and inflammation attenuation in adipose tissues \[[@B89-marinedrugs-18-00002]\]. Different authors highlighted the immune-stimulatory properties of PUFA \[[@B90-marinedrugs-18-00002],[@B91-marinedrugs-18-00002]\], as well as their anti-inflammatory properties \[[@B92-marinedrugs-18-00002]\].

Han et al. \[[@B93-marinedrugs-18-00002]\] tested the effects of EPA on macrophage RAW264.7 cell cultures. EPA increased macrophage proliferation rate, induced the release of nitric oxide and cytokines such as IL-1β, IL-6, TNF-α, and INF-γ through the activation of GPR120-mediated Raf kinases mitogen-activated protein kinases p44/p42 (ERK1/2)-inhibitor of nuclear factor kappa-B kinase subunit β (IKKβ)-nuclear factor kappa B p65 (NF-kB) signaling pathways. In this study, macrophage RAW264.7 cells were incubated in the presence of 0.6 to 3 μM EPA and their activation was analyzed after 24 h. DHA were found to modulate dendritic cell activities through improved expression of peroxisome proliferator-activated receptor gamma (PPAR γ). After 24 h, DHA altered the mature DC phenotype, increased macrophage inflammatory proteins 1α (MIP-1α) chemotaxis in immature DCs, and reduced the levels of IL-6, IL-10, and IL-12 in DCs \[[@B91-marinedrugs-18-00002]\]. After 6 days, DHA modulated the differentiation of immature DCs from monocytes (rise in the DC markers CD36, CD83, and CD86).

4.4. Astaxanthin {#sec4dot4-marinedrugs-18-00002}
----------------

Another important microalga-derived compound is astaxanthin (ASX). ASX, a carotenoid pigment, has been found in several freshwater and marine microorganisms, including bacteria, yeast, fungi, and microalgae, as well as in some aquatic organisms that feed on them. ASX is known to have antioxidant \[[@B115-marinedrugs-18-00002]\], anti-inflammatory \[[@B116-marinedrugs-18-00002]\], anti-obesity \[[@B117-marinedrugs-18-00002]\], cardiovascular \[[@B118-marinedrugs-18-00002]\] and anti-proliferative activities \[[@B1-marinedrugs-18-00002]\]. The use of ASX-containing products as human health food supplements is increased in the last years. In 2018, ASX had a market size of over US\$100 million \[[@B119-marinedrugs-18-00002]\]. ASX became an important compound in the global market \[[@B120-marinedrugs-18-00002]\] and its safety and uses have been widely discussed \[[@B119-marinedrugs-18-00002]\]. The commercially available astaxanthin approved by the Food and Drug Administration (FDA) is mainly derived from the microalga *Haematococcus pluvialis*, even if other cases are reported as well (e.g. from the bacterium *Paracoccus carotinifaciens*) \[[@B119-marinedrugs-18-00002]\]. It has a plethora of applications, such as eye health and vision \[[@B119-marinedrugs-18-00002]\], skin health \[[@B121-marinedrugs-18-00002]\] and body exercise performance and recovery \[[@B119-marinedrugs-18-00002]\]. In addition, it has applications in the treatment of Parkinson disease \[[@B122-marinedrugs-18-00002]\] and cancer \[[@B1-marinedrugs-18-00002]\].

ASX has been also found to enhance immune response in several studies. Park et al. \[[@B123-marinedrugs-18-00002]\] tested the effect of ASX in a randomized double-blind, controlled study. ASX was administered for 8 weeks at 2 or 8 mg/d. ASX increased natural killer cell cytotoxic activity, and increased the total T and B cell subpopulations. ASX has been found to increase the lymphocyte proliferation in in vitro mice model and increase the levels of IL-2 and INF-γ in ex vivo mice model \[[@B124-marinedrugs-18-00002]\]. Moreover, Davinelli et al. \[[@B125-marinedrugs-18-00002]\] tested the activity of ASX in mice model after *Helicobacter pylori* inoculation. The splenocytes from treated mice were isolated and the production of the cytokines involved in immune response to *H. pylori* was evaluated. The levels of the IL-2, IL-10, and INF-γ increased after 6 weeks of treatment.

5. Discussion {#sec5-marinedrugs-18-00002}
=============

Natural products from marine and freshwater microalgae have been widely studied in the last years highlighting their diversified activities, such as antioxidant, antibacterial, antitumor, anti-inflammatory, anti-hypertensive, cardioprotective, and antidiabetic \[[@B126-marinedrugs-18-00002],[@B127-marinedrugs-18-00002]\]. In addition, various studies have used an OSMAC approach in order to increase the production of specific metabolites \[[@B5-marinedrugs-18-00002],[@B42-marinedrugs-18-00002],[@B43-marinedrugs-18-00002]\]. Several active raw extracts, fractions, and pure compounds have been identified, however, they have not reached the clinical trials yet (<https://www.midwestern.edu/departments/marinepharmacology/clinical-pipeline.xml>). On the contrary, microalgal extracts and compounds have already found application in the nutraceutical and cosmetical sectors \[[@B128-marinedrugs-18-00002],[@B129-marinedrugs-18-00002],[@B130-marinedrugs-18-00002],[@B131-marinedrugs-18-00002],[@B132-marinedrugs-18-00002],[@B133-marinedrugs-18-00002],[@B134-marinedrugs-18-00002],[@B135-marinedrugs-18-00002]\].

Microalgae are, in fact, a rich resource of macronutrients and therefore, they have been proposed as a potential sustainable food source \[[@B128-marinedrugs-18-00002],[@B129-marinedrugs-18-00002],[@B130-marinedrugs-18-00002]\]. Recently, Neumann et al. \[[@B128-marinedrugs-18-00002]\] also analyzed nutrient contents of the microalgae *Chlorella vulgaris*, *Nannochloropsis oceanica, P. tricornutum* and tested their food safety in mice. The microalgal species most used as food supplements are *Chlorella* sp., *D. tertiolecta*, and *D. salina* \[[@B135-marinedrugs-18-00002]\]. In addition, *D. tertiolecta* and *Tetraselmis suecica* have been widely used as source of vitamin E for cosmetic formulation, and *D. salina* has been also used for the high content β-cryptoxanthin, which induces hyaluronic acid synthesis \[[@B134-marinedrugs-18-00002]\].

The immunomodulatory activity of microalgae has been reported only recently, and several active extracts or fractions have been identified as well as pure compounds. Further analyses have been performed to identify the optimal active concentrations, their mechanisms of action and possible applications.

In the last decades, immunotherapy has proved to be an efficient weapon against cancer, indeed several immunotherapies have been developed and placed in the market \[[@B136-marinedrugs-18-00002],[@B137-marinedrugs-18-00002]\]. Recent findings have allowed to actively use the immune system cells \[[@B28-marinedrugs-18-00002],[@B138-marinedrugs-18-00002]\]. In addition DCs have been investigated for the preparation of DC-based vaccine against tumor \[[@B139-marinedrugs-18-00002],[@B140-marinedrugs-18-00002]\]. DCs are the most efficient APCs \[[@B141-marinedrugs-18-00002],[@B142-marinedrugs-18-00002]\] and are also called "nature's adjuvant" to induce activation and specific expansion of cytotoxic T lymphocytes \[[@B143-marinedrugs-18-00002]\]. However, the costs of these innovative treatments are high, becoming a limiting factor for immunotherapy \[[@B144-marinedrugs-18-00002]\].

A good alternative to reduce the costs of the current treatments could be the production of immune-stimulatory compounds from marine sources and microalgae appeared to be excellent candidates. Different classes of microalgal-derived compounds have shown immune-stimulatory activity, such as sulfo-polysaccharides, sulfated lipids, polyunsaturated fatty acids, and astaxanthin. All these compounds are able to stimulate macrophage cells \[[@B2-marinedrugs-18-00002],[@B53-marinedrugs-18-00002]\], T-cell \[[@B56-marinedrugs-18-00002],[@B123-marinedrugs-18-00002]\], or dendritic cells \[[@B7-marinedrugs-18-00002],[@B77-marinedrugs-18-00002],[@B91-marinedrugs-18-00002]\] ([Figure 3](#marinedrugs-18-00002-f003){ref-type="fig"}). In addition, they are the most promising compounds that act as molecular adjuvants \[[@B58-marinedrugs-18-00002],[@B77-marinedrugs-18-00002]\] and are able to stimulate DC maturation and specific immune responses.

Nevertheless, the interesting properties of microalgae for human health applications have increased the exploration and exploitation of a plethora of possible source environments. Recent European Union-funded projects, under both the Research and Innovation funding programmes 7th Framework Programme and Horizon 2020 (FP7 and H2020 programs, respectively), focused on microalgal bioactivities and their possible market applications (e.g., EMBRIC, GIAVAP, PharmaSea and SUNBIOPATH) \[[@B145-marinedrugs-18-00002]\].

Marine-derived compounds discovery is a young branch of the science in comparison with immunotherapy ([Figure 4](#marinedrugs-18-00002-f004){ref-type="fig"}). The first vaccine was developed in 1769 \[[@B146-marinedrugs-18-00002]\] and about two thousand years later the first marine derived drug was approved \[[@B147-marinedrugs-18-00002]\]. But the rapid development and approval of new immune-therapeutic strategies \[[@B148-marinedrugs-18-00002],[@B149-marinedrugs-18-00002]\] and the large amount of new compounds from microalgae \[[@B1-marinedrugs-18-00002],[@B147-marinedrugs-18-00002],[@B150-marinedrugs-18-00002]\], may lead to the finding of new promising drugs for immunotherapy. The number of microalgal species producing immunomodulatory molecules has not yet been adequately characterized, and considering their huge chemical diversity, eco-friendly approach for sampling and easy culturing compared to macroorganisms, they could be promising new sources of immunomodulatory molecules \[[@B151-marinedrugs-18-00002]\]. Finally, the application of new bioengineering tools, such as CRISP/Cas9 system for gene editing and gene knock-out in marine algae, \[[@B152-marinedrugs-18-00002],[@B153-marinedrugs-18-00002]\] could be very promising in order to improve the production of microalgae enriched in molecules with immunomodulatory activity.

G.R. and C.L. conceived and co-wrote the paper. All authors have read and agreed to the published version of the manuscript.

This research was funded by the "Antitumor Drugs and Vaccines from the Sea (ADViSE)" project (PG/2018/0494374).

The authors declare no conflict of interest.

![Molecular structures of (**a**) sulfoquinovose, and (**b**) sulfoquinovosyldiacylglycerols.](marinedrugs-18-00002-g001){#marinedrugs-18-00002-f001}

![Molecular structures of (**a**) eicosapentaeonic acid (EPA) and (**b**) docosahexaeonic acid (DHA).](marinedrugs-18-00002-g002){#marinedrugs-18-00002-f002}

![Mechanisms of action of the most promising immunostimulatory compounds. Sulphate polysaccharides and polyunsaturated fatty acids trigger macrophage activation increasing cytokine and NO levels \[[@B2-marinedrugs-18-00002],[@B53-marinedrugs-18-00002],[@B93-marinedrugs-18-00002]\]; Sulfolipids increase the number of CD83-positive cells associate to mature dendritic cells \[[@B7-marinedrugs-18-00002]\], in turn dendritic cells generate active T cells \[[@B143-marinedrugs-18-00002]\] and prime an efficient Th1 cell response \[[@B154-marinedrugs-18-00002]\]. Astaxanthin improves T-cell response increasing INF-γ levels \[[@B123-marinedrugs-18-00002]\].](marinedrugs-18-00002-g003){#marinedrugs-18-00002-f003}

![Development of immunotherapy and marine derived drugs. The timeline highlights Food and Drug Administration (FDA) approval in the field of marine derived drugs discovery (**a**) and immunotherapy (**b**).](marinedrugs-18-00002-g004){#marinedrugs-18-00002-f004}

marinedrugs-18-00002-t001_Table 1

###### 

Marine microalgae synthesizing immunomodulatory compounds or possessing immunomodulatory properties. IL is for interleukin, PBMC is for human peripheral blood mononuclear cells, NA is for not available, w/v is for weight/volume.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Microalgae                    Extract/Fraction/Compound                                                                              Active Concentration   Mechanism/ Organism and Target Cells (or Model)                                                                                                                                                        Reference
  ----------------------------- ------------------------------------------------------------------------------------------------------ ---------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ -------------------------------------------------------------
  *Alexandrium tamarense*       Total Extract/Fractions                                                                                NA                     Activation of IL-6/Human PBMC                                                                                                                                                                          \[[@B49-marinedrugs-18-00002]\]

  *Chaetoceros calcitrans*      Fractions                                                                                              NA                     Activation of IL-6/Human PBMC                                                                                                                                                                          \[[@B49-marinedrugs-18-00002]\]

  *Chaetoceros socialis*        Total extract                                                                                          NA                     Activation of IL-6/Human PBMC                                                                                                                                                                          \[[@B49-marinedrugs-18-00002]\]

  *Chlorella stigmatophora*     Crude polysaccharide extracts                                                                          5 or 10 mg/kg          Activation of phagocytic activity - SRBC/Mouse                                                                                                                                                         \[[@B50-marinedrugs-18-00002]\]

  *Chlorella vulgaris*          Diet supplementation/ commercially available pills                                                     5 g/day                Improve of NK activity and serum level of INF-γ, IL-1β and IL-12/Human trials                                                                                                                          \[[@B55-marinedrugs-18-00002]\]

  *Dunaliella salina*           Diet supplementation of commercially available spray-dried preparations                                369, and 922.5 mg/kg   MiceNK and Macrophage activation/In vivo mice model                                                                                                                                                    \[[@B56-marinedrugs-18-00002]\]\
                                                                                                                                                                                                                                                                                                                                                                     \[[@B49-marinedrugs-18-00002]\]

  *Dunaliella salina*           Fractions                                                                                              NA                     Activation of IL-6/Human PBMC                                                                                                                                                                          \[[@B49-marinedrugs-18-00002]\]

  *Euglena gracilis*            β-Glucans                                                                                              150 μg/mL              Activation of NK cells and improve in inflammatory mediator/Human PBMC                                                                                                                                 \[[@B51-marinedrugs-18-00002],[@B52-marinedrugs-18-00002]\]

  *Gyrodinium impudicum*        Sulfated exopolysaccharides                                                                            0.1--10 μg/mL          Macrophage activation/Murine                                                                                                                                                                           \[[@B53-marinedrugs-18-00002],[@B59-marinedrugs-18-00002]\]

  *Skeletonema costatum*        Total Extract/Fractions                                                                                NA                     Activation of IL-6/Human PBMC                                                                                                                                                                          \[[@B49-marinedrugs-18-00002]\]

  *Skeletonema dohrnii*         Total Extract/Fractions                                                                                NA                     Activation of IL-6/Human PBMC                                                                                                                                                                          \[[@B49-marinedrugs-18-00002]\]

  *Skeletonema marinoi*         Total Extract                                                                                          NA                     Activation of IL-6/Human PBMC                                                                                                                                                                          \[[@B49-marinedrugs-18-00002]\]

  *Spirulina* sp.               Food supplement of condensed water-soluble extract of commercially available spray dried *Spirulina*   NA                     Augmentation of interferon production and NK cytotoxicity /Human trials                                                                                                                                \[[@B60-marinedrugs-18-00002],[@B61-marinedrugs-18-00002]\]

  *Tetraselmis chuii*           Orally administration of lyophilized microalgae                                                        50 or 100 g/Kg         Increase in hemolytic complement activity, phagocytic capacity and expression levels of β-defensin, major histocompatibility complex IIα and colony-stimulating factor receptor-1/Gilthead sea bream   \[[@B57-marinedrugs-18-00002]\]

  *Thalassiosira weissflogii*   Fractions                                                                                                                     Activation of IL-6/Human PBMC                                                                                                                                                                          \[[@B49-marinedrugs-18-00002]\]

  *Thraustochytriidae* sp.      Exopolysaccharides                                                                                     10^−3^ to 10^−9^ w/v   B-cells proliferation/Human                                                                                                                                                                            \[[@B54-marinedrugs-18-00002]\]

  *Tribonema* sp.               Sulfated polysaccharides                                                                               12.5--200 μg/mL        Macrophage proliferation and improved expression of cytokines/Mouse                                                                                                                                    \[[@B2-marinedrugs-18-00002]\]
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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###### 

Main polyunsaturated fatty acids (PUFAs) identified in selected microalgae. The table shows only the microalgae for which the most abundant PUFAs produced were reported, and corresponding references.

  Microalgae                      PUFA      Ref
  ------------------------------- --------- ----------------------------------
  *Amphidinium carterae*          ARA/EPA   \[[@B94-marinedrugs-18-00002]\]
  *Amphiprora hyaline*            EPA       \[[@B95-marinedrugs-18-00002]\]
  *Amphora coffeaeformis*         EPA/DHA   \[[@B96-marinedrugs-18-00002]\]
  *Chlamydomonas reinhardtii*     ω-3       \[[@B97-marinedrugs-18-00002]\]
  *Chlorella minutissima*         EPA       \[[@B98-marinedrugs-18-00002]\]
  *Cocconeis scutellum*           ω-3/ω-6   \[[@B99-marinedrugs-18-00002]\]
  *Conticribra weissflogii*       EPA/DHA   \[[@B96-marinedrugs-18-00002]\]
  *Cryptomonas* sp.               EPA/DHA   \[[@B100-marinedrugs-18-00002]\]
  *Cylindrotheca fusiformis*      EPA       \[[@B95-marinedrugs-18-00002]\]
  *Fragilaria pinnata*            EPA       \[[@B95-marinedrugs-18-00002]\]
  *Isochrysis galbana*            EPA/DHA   \[[@B101-marinedrugs-18-00002]\]
  *Karlodinium veneficum*         ω-3       \[[@B102-marinedrugs-18-00002]\]
  *Nannochloropsis gaditana*      EPA       \[[@B103-marinedrugs-18-00002]\]
  *Nannochloropsis* sp.           EPA       \[[@B104-marinedrugs-18-00002]\]
  *Nitzschia closterium*          EPA       \[[@B95-marinedrugs-18-00002]\]
  *Nitzschia laevis*              ARA/EPA   \[[@B105-marinedrugs-18-00002]\]
  *Nitzschia plea*                EPA       \[[@B106-marinedrugs-18-00002]\]
  *Parietochloris incisa*         ARA/EPA   \[[@B94-marinedrugs-18-00002]\]
  *Pavlova lutheri*               EPA/DHA   \[[@B107-marinedrugs-18-00002]\]
  *Phaeodactylum tricornutum*     EPA       \[[@B108-marinedrugs-18-00002]\]
  *Pleurochrysis carterae*        ω-3       \[[@B109-marinedrugs-18-00002]\]
  *Porphyridium purpureum*        ARA/EPA   \[[@B110-marinedrugs-18-00002]\]
  *Proschkinia complanatoides*    EPA       \[[@B111-marinedrugs-18-00002]\]
  *Rhizosolenia setigera*         EPA       \[[@B95-marinedrugs-18-00002]\]
  *Rhodomonas* sp.                EPA/DHA   \[[@B100-marinedrugs-18-00002]\]
  *Skeletonema costatum*          EPA       \[[@B112-marinedrugs-18-00002]\]
  *Skeletonema marinoi*           EPA       \[[@B113-marinedrugs-18-00002]\]
  *Storeatula major*              ω-3       \[[@B102-marinedrugs-18-00002]\]
  *Tetraselmis suecica*           EPA       \[[@B114-marinedrugs-18-00002]\]
  *Thalassionema nitzschioides*   EPA       \[[@B95-marinedrugs-18-00002]\]
  *Thalassiosira pseudonana*      ARA/EPA   \[[@B94-marinedrugs-18-00002]\]
  *Thalassiosira stellaris*       EPA       \[[@B95-marinedrugs-18-00002]\]
  *Thalassiothrix heteromorpha*   EPA       \[[@B95-marinedrugs-18-00002]\]
